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ABSTRACT 
Background MicroRNA-129-1 (miR-129-1) seems to 
behave as a tumour suppressor since its decreased 
expression is associated with different tumours such as 
glioblastoma multiforme (GBM). GBM is the most 
common form of brain tumours originating from glial 
cells. The impact of miR-129-1 downregulation on GBM 
pathogenesis has yet to be elucidated. 
Methods MiR-129-1 was overexpressed in GBM cells, 
and its effect on proliferation was investigated by cell 
cycle assay. MiR-129-1 predicted targets (CDK6, IGF1, 
HDAC2, IGF2BP3 and MAPK1) were also evaluated by 
western blot and luciferase assay. 
Results Restoration of miR-129-1 reduced cell 
proliferation and induced G1 accumulation, signiﬁcantly. 
Several functional assays conﬁrmed IGF2BP3, MAPK1 
and CDK6 as targets of miR-129-1. Despite the fact that 
IGF1 expression can be suppressed by miR-129-1, 
through 30-untranslated region complementary sequence, 
we could not ﬁnd any association between IGF1 
expression and GBM. MiR-129-1 expression inversely 
correlates with CDK6, IGF2BP3 and MAPK1 in primary 
clinical samples. 
Conclusion This is the ﬁrst study to propose miR129-1 
as a negative regulator of IGF2BP3 and MAPK1 and also 
a cell cycle arrest inducer in GBM cells. Our data 
suggests miR-129-1 as a potential tumour suppressor 
and presents a rationale for the use of miR-129-1 as a 
novel strategy to improve treatment response in GBM. 
INTRODUCTION 
Glioblastoma multiforme (GBM) is the most 
common and malignant form of the primary brain 
tumours in humans that originates from glial cells 
or their precursors within the central nervous 
system. Despite advances in cancer therapy strat­
egies, treatment of patients with GBM can be difﬁ­
cult due to heterogeneous and topographically 
diffused nature of the brain tumours.1 2 The 5 year 
survival rate of patients is very low at about 10%, 
which deﬁnes GBM as a life-threatening disease. 
Several pathways such as the RAS, tumour protein 
53 (TP53) and phosphoinositide kinase 3 (PIK3), 
as well as the cell cycle control pathways, have been 
identiﬁed to be disrupted in GBM.3 4 
For efﬁcient treatment of GBM, understanding the 
exact molecular mechanism of the disease is crucial. 
But, several mutations in various molecular pathways 
and different abnormalities’ contribution to the glio­
magenesis make this task difﬁcult to be achieved.5 
Interestingly, recent studies have indicated that 
there is a relationship between the mis-expression 
of microRNAs (miRNAs or miRs) and pathogenesis 
of different types of cancer, for example, colorec­
tal,6 lung,7 breast,8 hepatic,9 pancreatic cancer10 
and GBM.11 MiRNAs (non-coding RNAs approxi­
mately 20–25 nucleotide in length) regulate gene 
expression at the post-transcriptional level by tar­
geting cognate mRNAs containing partially comple­
mentary sequences in their 30-untranslated region 
(30-UTR). This results in the cleavage of the RNA 
or reduced level of the corresponding protein.12–15 
MiRNAs have also been demonstrated to play crit­
ical roles as a new and important class of onco­
genes and tumour suppressors in tumours. For 
example, let-716 in lung cancer and the miR15a/16 
cluster in chronic lymphocytic leukaemia17 act as 
tumour suppressors. In contrast, miR-17-92 cluster 
in malignant lymphoma and miR-155/BIC in 
Burkitt’s lymphoma act as oncogenes.18 
MiR-129 family is composed of two members: 
miR-129-1 located on chromosome 7q32 and 
miR-129-2 located on chromosome 11p11.2.19 
Interestingly, chromosome 7q32 is a frequently 
deleted region in many cancers.20 21 MiR-129 
family seem to behave as a tumour suppressor and 
their decreased expression has been shown in dif­
ferent tumours such as: gastric,22 bladder,23 and 
endometrial cancer,24 hepatocellular25 and colorec­
tal carcinoma,26 lung adenocarcinoma27 and 
GBM.11 However, the precise role of miR-129-1 in 
GBM cancer pathology remains to be deﬁned. 
In the current study, we scrutinised the tumour 
suppressive role of miR-129-1 in GBM cell lines and 
found that the overexpression of miR-129-1 inhibits 
cell proliferation and induces G1 arrest in GBM cell 
lines. Further analysis showed that IGF2BP3, CDK6 
and MAPK1, and not IGF1, are important targets of 
miR-129-1 in GBM cells. In addition, we could ﬁnd 
a downregulation in the expression level of 
miR-129-1 in majority of patients with GBM com­
pared with control samples. 
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MATERIAL AND METHODS 
Cell lines and patient sample collection 
Human glioma cell lines U87, A172, U251 and human embry­
onic kidney (HEK) 293 T cells were maintained in Dulbecco’s 
modiﬁed eagle’s medium supplemented with 10% fetal bovine 
serum (Hyclone, USA) and 1% antibiotics (100 U/mL penicillin 
and 100 mg/mL streptomycin sulfate). Cells were grown in 5% 
CO2 at 37°C. 
Fifteen fresh GBM tissues (WHO grade IV) and age-matched 
and sex-matched non-cancer postmortem brain tissues were 
obtained from Sina Hospital and Forensics Center, respectively 
(Tehran, Iran), in 2013 with informed written consent in 
accordance with the Declaration of Helsinki. All tissue samples 
were obtained at primary resection. None of the patients had 
undergone prior chemotherapy or radiation therapy. Patient 
samples were immediately sliced to <0.5 cm thick and main­
tained in approximately 10 μL reagent of RNALater per 1 mg of 
tissue (Qiagen) and stored at −20°C until usage. 
Plasmids, viral vectors construction and luciferase assay 
For gain-of-function studies, a genomic fragment spanning the 
miR-129-1 coding region was cloned into pLEX.JRed vector 
(pLEX-miR-129) and for loss-of-function studies pLenti-miR­
Off-129 construct was purchased from ABM Company (see 
online supplementary data). 
For luciferase assays, the partial lengths of IGF1, IGF2BP3 
and MAPK1 30-UTR, harbouring potential miR-129-1 target 
sites, were cloned downstream of the luciferase gene in the 
pSICHECK2 vector (Promega). For construction of 
Mut-miR-129-1, two mutations were created in the seed region 
Figure 1 MiR-129-1 reduced cell proliferation in glioblastoma multiforme (GBM) cell lines. (A) miR-129-1 expression evaluated by QRT-PCR in 
GBM cell lines, 2 and 3 days after transduction with pLEX-Ctrl, pLEX-Scr or pLEX-miR-129-1 relative to SNORD47 as an endogenous control. 
Columns, mean of three replicates; bars, SD (∗p<0.001). (B) Measurement of cell absorbance by MTT assay. MiR-129-1 impacts on cell proliferation 
were measured up to 96 h after transduction. Each time point was expressed as total absorbance at 570 nm after background subtraction (Y axis). 
Points, mean of three experiments; bars, SD. (C) Cell growth curves for U87-MG, A172 and U251 cells transduced with miR-129-1 and their 
respective controls. Transduction of pLEX-miR-129-1 decreased the cell proliferation, as compared with the cells transduced with pLEX-Ctrl or 
pLEX-Scr. Points, mean of three experiments; bars, SD. Three pLEX-Scr construct were used for each test and the values shown are the average 
obtained from them. 
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of the pre-miR-129-1 and mutated stem-loop structure was 
cloned in pGFP-V-RS vector. Luciferase activity was measured 
48 h after transfection using the Dual Luciferase Reporter Assay 
System (Promega) and the Renilla luciferase signal normalised to 
the Fireﬂy luciferase signal activity (see online supplementary 
data). 
To knockdown endogenous IGF2BP3, MAPK1 and IGF1 the 
small hairpin RNAs (shRNAs) were constructed and cloned into 
vector pGFP-V-RS (shIGF2BP3, shMAPK1 and shIGF1, respect­
ively). An empty shRNA vector (shCtrl) was used as a negative 
control (see online supplementary data). 
Gene expression analysis 
Total RNA was puriﬁed from cell lines or tissue specimens using 
Trizol (Invitrogen) according to the manufacturer’s protocol and 
reverse transcribed to cDNA using random hexamers (for 
mRNA genes), stem-loop RT speciﬁc primers (for miR-129-1 
and SNORD47) and M-MuLV RT (Promega). 
Real-time PCR for target mRNAs and miR-129-1 was per­
formed using Quantitect SYBR Green PCR Master Mix 
(Takara). QRT-PCR primer sequences are listed in online sup­
plementary table S1. 
In clinical samples, the mean of miR-129 Cts between all of 
the normal samples was determined and compared with the 
obtained Cts of each patient. The same procedure was per­
formed for SNORD47, as internal control gene, for normalisa­
tion of expression data. Based on the results, patients were 
divided into two groups: a group in which miR-129-1 gene 
expression level was lower than normal samples and the other 
in which miR-129-1 gene expression level was higher than 
normal samples. Subsequently, relative gene expression of 
IGF2BP3, IGF1 and MAPK1 was determined by comparing 
obtained Cts in patients with mean Cts of normal samples. 
Cell proliferation of infected cells 
A total of 5.0×105 cells for each of the GBM cell lines were 
seeded into 10 mL plates and transduced with Lentiviruses con­
taining empty vector (pLEX-Ctrl), encoding for scramble 
sequence of miR-129-1 (pLEX-Scr), miR-129-1 (pLEX-miR­
129-1) and miR-Off-129-1 (pLenti-III-miR-Off-129-1). Viable 
cells were collected and counted 2–4 days after infection by 
trypan blue exclusion using a ViCell counter (Beckman 
Coulter). 
MTT, chemosensitivity and apoptosis assays 
MTT assay was performed using Vybrant MTT Cell 
Proliferation Assay Kit, according to manufacturer’s protocol 
(Life Technologies). Absorbance was measured at 550 nm using 
a multiwell spectrophotometer (Bio-Tek). 
For chemosensitivity assay, U251 cells were seeded in 24-well 
plate and transduced with miR-Off-129-1. About 48 h after 
transduction, normal and transduced U251 cells were treated 
with LY294002 (20 mM), or PD98059 (20 mM) small molecular 
inhibitors, and incubated at 37°C, 5% CO2 for 48 h. At this 
point, MTT assay was performed as above. 
Cell apoptosis index was also assessed using Caspase 3 colori­
metric activity assay kit (Millipore, USA) according to manufac­
turer’s instruction. Luminescence of each sample was measured 
by a microtitre plate reader device (Eppendorf). 
Figure 2 Ectopic expression of miR-129-1 induced G1 arrest in glioblastoma multiforme (GBM) cell lines. Cells were transduced with pLEX-Ctrl, 
pLEX-Scr or pLEX-miR-129-1, collected after 72–96 h and analysed with ﬂow cytometry, indicating miR-129-1 induced a G1 accumulation in each of 
GBM cell lines at both time points. The maximum rate of G1 accumulation was observed in U251 cell line at 96 h (approximately 30% compared 
with the control). Each experiment was performed in triplicates. For transduction with pLEX-Scr, three pLEX-Scr constructs were used and the values 
shown are the average obtained from them. 
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Figure 3 MiR-129-1 overexpression inﬂuence protein and mRNA levels of target genes in Glioblastoma multiforme (GBM) cell lines. Endogenous 
IGF2BP3 (A), MAPK1 (B), IGF1 (C), CDK6 (D) and HDAC2 (E) protein and mRNA expression were measured at 72 h post-transduction of miR-129-1 in 
GBM cell lines. β-Actin was used as an internal control in QRT-PCR. For IGF2BP3 and MAPK1, transduction of miR-129-1 induced a decrease in the 
mRNA and protein levels in all three cell lines. Because of low expression of IGF1 in U87-MG and A172 cell lines, the expression level was analysed 
only in U251. For CDK6 and HDAC2, there were no signiﬁcant variations in the levels of their mRNAs compared with the controls. Western blotting 
of CDK6 indicated a reduction in protein level in three GBM cell lines, whereas no signiﬁcant changes were found in HDAC2 protein expression of 
GBM cell lines in transduced cells compared with that of the control cells. Protein normalisation was performed with β-actin. Columns, mean of 
three different experiments; bars, SD; NC: negative control (cells did not have any treatments); (∗p<0.05, ∗∗p<0.001). In the case of pLEX-Scr, 
transduction with three pLEX-Scr construct was performed and the values shown are the average obtained from them. 
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Cell-cycle analysis 
For cell cycle analysis, U87-MG, A172 and U251 cells were 
seeded in 24-well plates, and transduced with pLEX-Ctrl, 
pLEX-Scr or pLEX-miR-129, and collected after 3–4 days.  
Afterwards, cellular DNA content was evaluated by ﬂow cyto­
metry and obtained data were analysed using Flowjo 
programme. 
In order to ﬁnd the impact of IGF1 on cell cycle progression, 
105 cells of U251 line were transduced with pLEX-miR-129-1 
in 12-well plates. After 48 h, the conditioned medium was 
replaced with medium supplemented with 20 ng/mL IGF1 in 
test group. Cells were collected and cell cycle analyses were per­
formed 48 h later, as described in online supplementary data. 
Western blot 
Western blotting analysis for CDK6, MAPK1, IGF2BP3, IGF1 
and β-actin (antibodies purchased from Abcam) was carried out 
as mentioned in online supplementary data. 
Database prediction of miRNA targets 
The miRNA-129-1 targets were predicted using TargetScan web 
server (http://www.targetscan.org, V.5.1). Biological processes of 
this target list were analysed using PANTHER (http://www. 
pantherdb.org, V.7). Furthermore, DIANA-miRPath program 
(http://diana.cslab.ece.ntua.gr/pathways/) using DIANA-microT­
3.0-Strict was used to predict and analyse conserved targets for 
hsa-miR-129-1 in the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) database. 
Statistical analysis 
All experiments were performed at least three times, presented 
as mean± SD and analysed by student’s t test. p Values of ≤0.05 
were considered as statistically signiﬁcant. 
Additional information can be found in the online supple­
mentary material. 
RESULTS 
MiR-129-1 inhibits cell proliferation in GBM cell lines 
It has been reported that miR-129-1 is downregulated in GBM 
cancer, but the role of this miRNA in GBM carcinogenesis and 
tumour growth needs to be clariﬁed.11 28 To investigate the bio­
logical effect of miR-129-1, three GBM cell lines (U87-MG, 
A172 and U-251) were transduced with pLEX-miR-129-1, 
pLenti-miR-Off-129-1, pLEX-Ctrl and pLEX-Scr and evaluated 
for cell proliferation, cell cycle and apoptosis (see online supple­
mentary ﬁgure S1). 
The successful overexpression of miR-129-1 in the cells was 
conﬁrmed by QRT-PCR (ﬁgure 1A). After cell transduction, 
according to MTT assay, ectopic expression of miR-129-1 
resulted in a signiﬁcant shrinkage in cell absorbance as com­
pared with that of the control groups. Observed phenotype 
could compensate using pLenti-miR-Off-129-1 (ﬁgure 1B). 
Absorbance reduction in MTT assay could be partially due to 
the induction of apoptosis or disruption of cell proliferation via 
several mechanisms such as cell cycle arrest. Thus, we next 
explored the effect of miR-129-1 on apoptosis and cell cycle 
regulation. 
Caspase 3 activity assay showed that miR-129-1 has no signiﬁ­
cant effect on the induction of caspase 3-mediated apoptosis 
(data not shown). So, we investigated the role of miR-129-1 in 
cell proliferation index. Interestingly, an increase in miR-129-1 
expression caused signiﬁcant decrease in cell proliferation rate 
of GBM cell lines regarding control groups in all three cell 
Figure 4 MiR-129-1 downregulation via anti-miR raises protein and 
mRNA levels of target genes in glioblastoma multiforme (GBM) cell 
lines. Endogenous IGF2BP3 (A) and MAPK1 (B) mRNAs and CDK6 (C) 
protein expressions were analysed according to miR-129-1 inhibition by 
pLenti-miR-Off-129-1. Transduction of pLenti-miR-Off-129-1 into GBM 
cells was followed by a slight increase in mRNAs and protein levels of 
target genes expect of IGF1. β-Actin was used as an internal control. 
Columns, mean of three different experiments; bars, SD; (∗p<0.05). 
lines. Depletion of miR-129-1 in transduced GBM cell lines 
using pLenti-miR-Off-129-1 diminishes reduction of cell prolif­
eration, indicating that the observed effect was limited to 
miR-129-1 activities (ﬁgure 1C). 
Next, we evaluate the inﬂuence of endogenous miR-129-1 
downregulation via using pLenti-miR-Off-129-1 on prolifer­
ation of control GBM cells. Globally, cell proliferation was 
slightly increased in the three cell lines (see online supplemen­
tary ﬁgure S2). 
The effect of miR-129-1 on cell cycle progression was also 
examined using ﬂow cytometry. The results indicate that 
miR-129-1 triggered more accumulation of cells at the G1 stage 
(59.3% at 72 h and 73.4% at 96 h) as compared with that of 
pLEX-Ctrl control (43.01% at 72 h and 55.67% at 96 h) in 
U87-MG cells, whereas, the number of cells in S phase and 
G2/M phase decreased from 32.21% and 24.36% at 72 h and 
27.69% and 15.76% at 96 h in pLEX-Ctrl control group to 
24.06% and 13.93% at 72 h and 13.7% and 8.83% at 96 h in 
Kouhkan F, et al. J Med Genet 2016;53:24–33. doi:10.1136/jmedgenet-2015-103225 28 
Downloaded from http://jmg.bmj.com/ on October 1, 2016 - Published by group.bmj.com 
Cancer genetics 
Figure 5 Interaction between miR-129-1 and 30-untranslated region (30-UTR) binding sites of target genes. The 30-UTR of IGF1 (A), MAPK1 (B) and 
IGF2BP3 (C) containing miR-129-1 target sites were cloned in the pSICHEK2 reporter vector and co-transfected with the pLEX-miR-129-1 expression 
vector in HEK293 cells for luciferase assays. (D) For construction of Mut-miR-129-1, two mutations were created in seed region of miR-129-1 and 
mutated pre-miR-129-1 was cloned in pGFP-V-RS. (E) MiR-129-1 expression signiﬁcantly inhibited the luciferase activity of IGF2BP3, IGF1 and 
MAPK1 30-UTRs. Luciferase activity was detected at 48 h after transfection. The empty pLEX and Mut-miR-129-1 vectors were used as negative 
controls. MiR-129-1 overexpression inhibited luciferase activity in the IGF2BP3, MAPK1 and IGF1 vector but had no effect on the control. MiR-129-1 
mature sequence is indicated in purple colour. The mutated forms of the bases were presented as letter in the ≤. Data shown are mean values±SD 
of the ratio of luciferase activity, obtained from at least three independent experiments; (∗p<0.001). 
pLEX-miR-129-1-treated group of U87 cell lines. Comparable 
results were also observed in A172 and U251 cells (ﬁgure 2). 
Taken together, these results demonstrated that miR-129-1 
could inhibit the proliferation of GBM cells in vitro. 
Upregulation of miR-129-1 reduced the expression level of 
IGF1, IGF2BP3, MAPK1 and CDK6 in GBM cell lines 
To identify the molecular networks through which miR-129-1 
exerts its inﬂuence on cell cycle, analysis of conserved mRNA 
targets of miR-129-1 (∼540 targets) was carried out using 
TargetScan program and then gene classiﬁcation was performed 
by PANTHER.29 30 Online supplementary ﬁgure S3A shows the 
biological processes and gene sets for predicted miR targets by 
TargetScan. In a similar approach, we used the DIANA miRPath 
program31 to predict miR-129-1 targets (∼1600) with the 
DIANA-microT-3.0-Strict algorithm32 followed by comparison 
with the KEGG biological pathways33 (see online supplementary 
ﬁgure S3B). A number of remarkable molecular networks were 
found as miR-129-1 targets, including cancer signalling, PI3K/ 
AKT and MAPK signalling, all of which are known as important 
pathways in tumour development. The results of biological pro­
cesses analysis by PANTHER indicated that 72 genes are 
involved in cell cycle (see online supplementary table S3). By 
comparing 72 cell cycle genes with genes affecting cancer pro­
gression, 12 genes are found to be involved in both categories. 
Among them ﬁve genes, MAPK1, HDAC2, IGF1, IGF2BP3 and 
CDK6, those which linked to G1/S arrest in literature and had 
high score in TargetScan, were selected for further analysis. 
To evaluate if these ﬁve predicted proteins could be considered 
as miR-129-1 targets, their mRNA levels were compared in cells 
transduced with pLEX-Ctrl, pLEX-Scr and pLEX-miR-129-1. 
After transduction (72 h), mRNA expression levels of candidate 
genes were determined by QRT-PCR analysis. IGF2BP3 and 
MAPK1 genes were signiﬁcantly downregulated in U87-MG 
(4.34-fold and 2.94-fold respectively), A172 (4-fold and 
2.4-fold) and U251 (4.89-fold and 3.5-fold) cell lines, compared 
with negative controls (ﬁgure 3A, B). Similarly, the protein 
levels of IGF2BP3 and MAPK1 were reduced in all three cell 
lines, with increased miR-129-1 expression. Analysis of IGF1 
was performed only in U251 cell line (1.45-fold and 1.3-fold 
downregulation in mRNA and protein, respectively, in compari­
son with the control group) because its expression was too low 
and undetectable in A172 and U87-MG cell lines (ﬁgure 3C). 
There was no differences in CDK6 and HDAC2 mRNA expres­
sion between transduced and control cells. So, we analysed 
CDK6 and HDAC2 protein levels by western blot after 
miR-129-1 overexpression and found that protein level of 
CDK6, but not HDAC2, decreased by factor of 2.5 in all cell 
lines (ﬁgure 3D, E). 
To further investigate miR-129-1 targets, GBM cell lines were 
transduced with anti-miR-129-1 virus particles. The results 
demonstrated a trend towards a slight increase in IGF2BP3 and 
MAPK1 mRNAs and CDK6 protein (ﬁgure 4A, C), although 
there was no signiﬁcant increase in the IGF1 expression level 
between pLenti-miR-Off-129-1-treated group and control 
group. 
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Figure 6 Reduced expression of IGF2BP3 and MAPK1 promotes G1 arrest. (A) Expression levels of predicted mRNAs were evaluated by Q-RT-PCR 
in U251 cells, 72 h after transfection of shIGF2BP3, shMAPK1, shIGF1 and shCtrl. (B) Cell cycle of U251 cells were transfected with each of the 
shRNA vectors and shCtrl. Transfection of U251 cells with shIGF2BP3 and shMAPK1 signiﬁcantly increased accumulation of G1 cells. However, the 
number of G1 cells in shIGF1-treated cells was not signiﬁcantly different from the cells treated with shCtrl vector. (C) Stimulation of U251 cells by 
IGF1 did not rescue miR-129-1-induced G1 arrest (p>0.05). About 48 h after transduction, 20 ng/mL IGF1 was added to conditional cell media of 
U251 cells. Next, cell cycle assays were performed 48 h after IGF1 addition. (D) Proliferation was measured by MTT assay 48 h after treatment of 
pLEX-miR-129-1-transduced U251 cells with dimethyl sulfoxide (DMSO) (negative control), LY294002 (20 mM) or PD98059 (20 mM). This is clear 
that DMSO-treated pLEX-miR-129-1 U251 cells grow slower than control U251 cells. Furthermore, both LY294002-treated and PD98059-treated 
control U251 cells illustrate faster growth than pLEX-miR-129-1-transducted U251 cells, indicating that miR-129-1 overexpression through repression 
of both of these pathways involved inhibition of glioma proliferation rate. Data were the averages of at least three independent runs; bars, SD 
(∗p<0.01, ∗∗p<0.001). 
MiR-129-1 targets IGF1, IGF2BP3 and MAPK1 
To validate that IGF1, IGF2BP3 and MAPK1 are direct targets 
of miR-129-1, the 30-UTRs of these three genes were cloned 
into the psiCHECK-2 plasmid (the predicted binding sites for 
miR-129-1 are shown in ﬁgure 5A–C) and cotransfected with 
wild type (WT) miR-129-1 or Mut-miR-129-1 into HEK293 T 
cells. Since, there is more than one recognition site in 30-UTR of 
each target; for negative control, seed sequence of miR-129-1 
was mutated instead of creating mutations in each recognition 
site of targets. Speciﬁcally, in the presence of the 
WT-miR-129-1 expression vector, the constructs bearing the 
30-UTR of IGF1, IGF2BP3 and MAPK1 mRNA showed 
decreases in luciferase activity (ﬁgure 5D). The suppression was 
speciﬁc to the predicted miR-129-1 target sites, as mutations in 
the seed region abrogated the interactions. 
IGF2BP3 and MAPK1 are involved in miR-129-1 dependent 
cell cycle arrest 
In order to investigate the association between miR-129-1 anti-
proliferative effect and targeting predicted mRNAs, U251 cells 
were transfected with each of shIGF2BP3, shMAPK1, shIGF1 
or shCtrl vectors. To avoid erroneous off-target effect, two 
different shRNA target sequences were used, and their silence 
efﬁciency were examined by QRT-PCR (ﬁgure 6A). Intriguingly, 
mRNA knockdown resulted in G1 accumulation of the cells 
transfected with shIGF2BP3 and shMAPK1, but not shIGF1, 
vectors compared with the cells transfected with scrambled 
control (ﬁgure 6B). Our data indicate that, among the examined 
targets, only IGF2BP3 and MAPK1 knockdown recapitulates 
the antiproliferative effect of miR-129-1. 
To further support these ﬁndings, we tried to determine 
whether IGF1 could revert the inhibition of cell proliferation 
caused by miR-129-1 overexpression in U251 cells. Therefore, 
transduced U251 cells were stimulated with 20 ng/mL IGF1 and 
cell cycle analysis was performed after 48 h. The assays obviously 
indicated that the ectopic expression of IGF1 has no effect on 
the suppression of G1/S transition (p>0.05, ﬁgure 6C). 
The mechanism underlying the antiproliferative effect of 
miR-129-1 was investigated using LY294002 and PD98059 
small molecules which inhibit PI3K/AKT and MAPK/ERK sig­
nalling pathways, respectively. For this purpose, U251 cells were 
divided into two groups, one of them was treated with either of 
the small molecules, which represent the control group. The 
other one was treated with both miR-129-1 and one of the 
Kouhkan F, et al. J Med Genet 2016;53:24–33. doi:10.1136/jmedgenet-2015-103225 30 
Downloaded from http://jmg.bmj.com/ on October 1, 2016 - Published by group.bmj.com 
Cancer genetics 
small molecules. We observed a signiﬁcant decrease in the prolif­
eration of cells treated with both miR-129-1 and small mole­
cules in comparison with control group (ﬁgure 6D). 
Thus, these results together emphasised miR-129-1 downre­
gulation as a causal factor involved in augmenting GBM cell 
proliferation through modulating these two major 
pro-oncogenic pathways presumably by targeting IGF2BP3, 
MAPK1 and CDK6. 
IGF2BP3, MAPK1 and CDK6 expression correlate inversely 
with miR-129-1 expression level in clinical GBM samples 
MiR-129-1 overexpression in GBM cell lines provided some 
important information about the mechanism of its action in regu­
lating genes. To obtain insights into the role of miR-129-1 in 
‘steady-state’ target gene regulation in GBM, we correlated 
miR-129-1 expression level with identiﬁed target mRNA 
expression levels in 15 primary GBM and 15 normal brain 
samples. The expression level of miR-129-1 is reduced up to 
50% (p<0.0001) in 67% (10 out of 15) of GBM cancer tissues 
compared with the non-cancerous brain tissues. Subsequently, 
based on the mean expression level of miR-129-1 in normal 
samples, patients were divided into two groups. The ﬁrst group 
had lower expression than reference (≤1) and the other group 
showed higher expression levels compared with the reference 
(>1, p=0.001). The distributions of IGF1, IGF2BP3 and 
MAPK1 mRNA levels and CDK6 protein expression level in 
GBM samples are shown in ﬁgure 7A–F. The median expression 
levels of IGF2BP3, MAPK1 and CDK6 were signiﬁcantly higher 
in the tumours expressing lower levels of miR-129-1 compared 
with those expressing higher levels of miR-129-1. However, 
there was no signiﬁcant difference between median expression 
levels of IGF1 between two groups. Consistent with the cell line 
Figure 7 Direct correlation of miR-129-1 and IGF2BP3, MAPK1 and CDK6 expression levels in clinical glioblastoma multiforme (GBM) tissues. (A) 
Distribution of relative miRNA-129-1 gene expression in GBM samples. (B) Distribution of GBM samples according to low and high expression of 
miR-129-1. (C) Distribution of relative gene expression of IGF1 in GBM samples according to miRNA-129-1 levels, p=0.39. (D) Distribution of relative 
gene expression of IGF2BP3 in GBM samples according to miRNA-129-1 levels, p=0.007. (E) Distribution of relative gene expression of MAPK1 in 
GBM samples according to miRNA-129-1 levels, p=0.006. (F) Distribution of relative CDK6 protein concentration in GBM samples according to 
miRNA-129-1 levels, p=0.013. (G) Model of cell cycle progression inhibited by tumour suppressor miR-129-1 through IGF2BP3-mediated, 
MAPK1-mediated and CDK6-mediated pathways. Data represent the mean of at least three independent experiments. Circles represent the 
expression levels for individual patients. The results are relative gene expression after normalisation with SNORD47 for miR-129-1 and β-actin for 
target genes using 2−ΔΔCt method. Horizontal lines represent the mean. 
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data, these results additionally proved that miR-129-1 expression 
affects the expression of predicted target genes except for IGF1. 
DISCUSSION 
Global alterations in miRNA expression have been illustrated in 
34 35a large number of malignancies.18 Some studies have 
reported the downregulation of miR-129-1 expression in GBM 
tumors11 28 but its function remains unknown.36 Here, our 
results clearly demonstrate that miR-129-1 acts as a tumour sup­
pressor gene in GBM and its overexpression prevents cells from 
completing the G1–S transition and delays the cell cycle pro­
gression of U87-MG, A172 and U-251 GBM cell lines. These 
results conﬁrm previously published data in mouse lung epithe­
lial (E10) cells and human lung adenocarcinoma cell line.22 27 
In order to obtain an insight into the cell cycle arrest in the 
presence of miR-129-1, we tried to identify putative targets of 
this miRNA. By recruiting KEGG/DIANA algorithm, we found 
most of miR-129-1 target genes associated with cancer develop­
ment. Moreover, TargetScan/PANTHER search algorithm results 
identiﬁed genes that have important role in cell cycle. Among 
these targets, ﬁve shared genes (IGF1, IGF2BP3, MAPK1, 
HDAC2 and CDK6), whose roles in G1/S arrest have been shown 
37–39in various studies, were chosen for more investigation.27 
Although two putative miR-129-1-binding site predicted by 
TargtScan in 30-UTR of HDAC2 gene, our analysis showed no sig­
niﬁcant changes in the HDAC2 mRNA or protein level. These 
data indicate that miR-129-1 does not act through HDAC2. 
IGF-1 activates PI3K/AKT/GSK-3β pathway, leading to an 
increase in GSK-3β phosphorylation. This stabilises cyclin D1 
and downregulates CDK inhibitors (p27KIP1 and p57KIP2), all 
contributing to G1/S regulation.38 40 Luciferase assay results 
demonstrated that miR-129-1 targets IGF1. However, stimula­
tion of U251 cells by IGF1 could not rescue the inhibitory 
effect of miR-129-1. In addition, no signiﬁcant difference was 
found in IGF1 expression level between GBM clinical and 
normal samples. These results indicate that although IGF1 is 
one of the targets of miR-129-1, it does not play a major role in 
GBM pathogenesis. There are two explanations. First is the 
presence of other important factors involved in the mechanism 
of miR-129-1 antiproliferative effect. 
Second, in a recent study, Masamha et al showed that 
CFIm25 downregulated in GBM cell lines.41 CFIm25 has a key 
role in mRNA alternative polyadenylation. Downregulation of 
CFIm25 results in a preferred proximal site mRNA polyadenyla­
tion (relative to stop codon). This inclination towards proximal 
site leads to the removal of negative regulatory elements such as 
miRNA target sequences within the 30-UTR of genes. 
Elimination of regulatory elements preserves mRNA, mostly 
associated with cell cycle and tumour development, from deg­
radation through miRNA targeting system. This may be the 
reason for lack of correlation between IGF-1 and miR-129-1 in 
GBM cell lines. 
Moreover, we showed that miR-129-1 targets MAPK1, 
IGF2BP3 and CDK6. Our results were further conﬁrmed by 
luciferase assay and shRNA knockdown. Remarkably, low 
miR-129-1 expression level is correlated with higher expression 
levels of these genes in GBM clinical samples. As shown in 
ﬁgure 7G, IGF2BP3 elevates IGF2 protein concentration via 
increasing the stability of IGF2 mRNA.39 42 43 IGF2 ligand was 
originally discovered as a mitogen; its mitogenic effect is 
mediated through binding to IGF-1 receptor and activation of 
MAPK/ERK and PI3 K/AKT cascades.44 MAPK/ERK pathway, in 
turn, promotes G1–S transition by increasing the expression 
level of cyclin D1 and CDK4/6 genes.45 46 Hence, targeting 
IGF2BP3, MAPK1 and CDK6 by miR-129-1 decreases the 
MAPK/ERK and PI3K/AKT cascades which lead to the post­
ponement of G1–S transition in cell cycle. Collectively, our 
results suggest miR-129-1 as a tumour suppressor that downre­
gulates the components of extrinsic and intrinsic signalling path­
ways, which have critical role in the proliferation of GBM cells. 
Further evidence came from the use of pharmacological inhibi­
tors of PI3K/AKT and MAPK/ERK pathways, indicating that the 
antiproliferative effect of miR-129-1 can be mediated through 
these pathways. 
Finally, we elucidated that miR-129-1 is downregulated in 
GBM cancer tissues compared with adjacent normal brain 
tissues and inhibits cell proliferation in GBM cell lines without 
inducing apoptosis in vitro. The exact underlying mechanism 
that is responsible for the downregulation of miR-129-1 has yet 
to be identiﬁed in GBM samples, but there is evidence that the 
hypermethylation of the promoter region can be the reason for 
this phenomenon.6 47  
Overall, our ﬁndings identify miR-129-1 as one of the 
tumour suppressor microRNAs that can be useful in getting a 
better understanding of GBM cancer pathogenicity. 
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